rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
Specifications
- Classify
- Protein therapeutics that interfere with a molecule or organism: Cancer
- Therapeutic
- Rituximab
- Trade Name
- rituximab
- Function
- Chimeric (human/mouse) mAb that binds cD20, a transmembrane protein found on over 90% of B-cell non-Hodgkin's lymphomas (NHL); synergistic effect with some small-molecule chemotherapeutic agents has been demonstrated in lymphoma cell lines
- Examples of Clinical Use
- Relapsed or refractory low-grade or follicular cD20+ B-cell NHL, primary low-grade or follicular cD20+ B-cell NHL in combination with cvP chemotherapy; diffuse large B-cell cD20+ NHL in combination with cHOP or other anthracyline- based chemotherapy; rheumatoid arthritis in combination with methotrexate
References
- Synonyms
- AntiCD20, Ig gamma-1 chain C region
- UniProt
- P01857
- Genbank
- J00228
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: